Chemotherapy Induced Neutropenia – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Chemotherapy Induced Neutropenia – Pipeline Review, H2 2017’, provides an overview of the Chemotherapy Induced Neutropenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia

The report reviews pipeline therapeutics for Chemotherapy Induced Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chemotherapy Induced Neutropenia therapeutics and enlists all their major and minor projects

The report assesses Chemotherapy Induced Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

BeyondSpring Pharmaceuticals Inc

Biocon Ltd

Bolder Biotechnology Inc

Cellerant Therapeutics Inc

Chong Kun Dang Pharmaceutical Corp

Cinfa Biotech SL

Dr. Reddy's Laboratories Ltd

Gene Techno Science Co Ltd

Generon (Shanghai) Corp Ltd

Genexine Inc

GlycoMimetics Inc

Hanmi Pharmaceuticals Co Ltd

Intas Pharmaceuticals Ltd

Lupin Ltd

Mycenax Biotech Inc

Myelo Therapeutics GmbH

Nohla Therapeutics Inc

Octapharma AG

Pangen Biotech Inc.

Pfenex Inc

Pfizer Inc

Reliance Life Sciences Pvt Ltd

Richter Gedeon Nyrt

Sandoz International GmbH

USV Pvt Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Chemotherapy Induced Neutropenia - Overview 7

Chemotherapy Induced Neutropenia - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 16

Chemotherapy Induced Neutropenia - Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development 25

BeyondSpring Pharmaceuticals Inc 25

Biocon Ltd 25

Bolder Biotechnology Inc 26

Cellerant Therapeutics Inc 26

Chong Kun Dang Pharmaceutical Corp 27

Cinfa Biotech SL 27

Dr. Reddy's Laboratories Ltd 28

Gene Techno Science Co Ltd 28

Generon (Shanghai) Corp Ltd 29

Genexine Inc 29

GlycoMimetics Inc 30

Hanmi Pharmaceuticals Co Ltd 30

Intas Pharmaceuticals Ltd 31

Lupin Ltd 31

Mycenax Biotech Inc 32

Myelo Therapeutics GmbH 32

Nohla Therapeutics Inc 33

Octapharma AG 33

Pangen Biotech Inc. 34

Pfenex Inc 34

Pfizer Inc 35

Reliance Life Sciences Pvt Ltd 35

Richter Gedeon Nyrt 36

Sandoz International GmbH 36

USV Pvt Ltd 37

Chemotherapy Induced Neutropenia - Drug Profiles 38

BBT-007 - Drug Profile 38

BBT-015 - Drug Profile 39

BBT-018 - Drug Profile 40

Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile 41

Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile 42

EC-18 - Drug Profile 43

eflapegrastim - Drug Profile 45

F-627 - Drug Profile 48

filgrastim - Drug Profile 50

filgrastim - Drug Profile 51

filgrastim - Drug Profile 53

filgrastim - Drug Profile 54

filgrastim - Drug Profile 55

filgrastim - Drug Profile 56

filgrastim - Drug Profile 57

filgrastim - Drug Profile 58

GMI-1271 - Drug Profile 59

GW-003 - Drug Profile 67

HSA-GCSF - Drug Profile 68

lenograstim - Drug Profile 69

Myelo-001 - Drug Profile 70

pegfilgrastim - Drug Profile 72

pegfilgrastim - Drug Profile 74

pegfilgrastim - Drug Profile 75

pegfilgrastim - Drug Profile 76

pegfilgrastim - Drug Profile 77

pegfilgrastim - Drug Profile 78

pegfilgrastim - Drug Profile 79

pegfilgrastim - Drug Profile 80

pegfilgrastim - Drug Profile 81

pegfilgrastim - Drug Profile 82

pegfilgrastim - Drug Profile 83

pegfilgrastim - Drug Profile 84

pegfilgrastim - Drug Profile 85

pegfilgrastim - Drug Profile 86

pegfilgrastim - Drug Profile 87

pegfilgrastim - Drug Profile 89

pegfilgrastim - Drug Profile 90

plinabulin - Drug Profile 91

romyelocel-L - Drug Profile 97

WBI-2100 - Drug Profile 100

YPEG-Filgrastim - Drug Profile 101

Chemotherapy Induced Neutropenia - Dormant Projects 102

Chemotherapy Induced Neutropenia - Discontinued Products 104

Chemotherapy Induced Neutropenia - Product Development Milestones 105

Featured News & Press Releases 105

Appendix 116

Methodology 116

Coverage 116

Secondary Research 116

Primary Research 116

Expert Panel Validation 116

Contact Us 116

Disclaimer 117

List of Tables

List of Tables

Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Biocon Ltd, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Bolder Biotechnology Inc, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Cellerant Therapeutics Inc, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Cinfa Biotech SL, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Dr. Reddy's Laboratories Ltd, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Gene Techno Science Co Ltd, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Generon (Shanghai) Corp Ltd, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Genexine Inc, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by GlycoMimetics Inc, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Intas Pharmaceuticals Ltd, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Lupin Ltd, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Mycenax Biotech Inc, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Myelo Therapeutics GmbH, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Nohla Therapeutics Inc, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Octapharma AG, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Pangen Biotech Inc., H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Pfenex Inc, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Pfizer Inc, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Richter Gedeon Nyrt, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by Sandoz International GmbH, H2 2017

Chemotherapy Induced Neutropenia – Pipeline by USV Pvt Ltd, H2 2017

Chemotherapy Induced Neutropenia – Dormant Projects, H2 2017

Chemotherapy Induced Neutropenia – Dormant Projects, H2 2017 (Contd..1), H2 2017

Chemotherapy Induced Neutropenia – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports